NET ASSET VALUE – 31 October 2024

MARKN.

On the 31 October 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,377 million and NAV per share was SEK 56.06.

Allocation of NAVShare of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV
Product Development    
Prokarium42%4886.2511.1%
Xspray Pharma18%3514.508.0%
Empros Pharma79%2042.624.7%
KAHR Medical31%2022.594.6%
Atrogi37%1762.254.0%
Lipum57%1732.224.0%
Xintela56%1431.843.3%
Microbiotica11%1391.783.2%
Mendus24%1231.572.8%
Geneos Therapeutics12%1031.312.3%
Toleranzia66%901.152.1%
EpiEndo Pharmaceuticals9%580.741.3%
Synerkine Pharma43%530.681.2%
AnaCardio19%520.661.2%
Egetis Therapeutics2%310.400.7%
Buzzard Pharmaceuticals14%290.370.7%
Vitara Biomedical8%290.370.7%
Sixera Pharma23%260.330.6%
Alder Therapeutics21%170.220.4%
Amarna Therapeutics58%120.150.3%
Strike Pharma16%90.110.2%
Total 2,50732.1157.3%





Commercial Growth   
NorthX Biologics92%1892.424.3%
Symcel31%1692.163.9%
Provell Pharmaceuticals72%750.961.7%
Chromafora31%730.931.7%
Nanologica38%710.911.6%
A3P Biomedical8%420.541.0%
Frontier Biosolutions2%190.250.4%
Bohus Biotech45%170.210.4%
Total 6548.3814.9%





Limited Partnerships, total 941.212.2%
     
Assets related to Portfolio companies 3164.057.2%
Other assets and liabilities 80510.3118.4%
     
Net asset value 4,37756.06100.0%
  

 

    

* indirect shares in Provell Pharmaceuticals

Datum 2024-11-04, kl 08:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet